AMS gains FDA approval for UroLume Endoprosthesis stent for male urinary obstruction.
This article was originally published in The Gray Sheet
Executive Summary
AMERICAN MEDICAL SYSTEMS UROLUME ENDOPROSTHESIS PMA APPROVAL MAY 6 brings to the U.S. market the first urological stent for treatment of bulbar urethral stricture in males. Pfizer subsidiary AMS says it will launch the stent "soon" through its direct sales force in the U.S. and a combination of direct reps and distributors overseas.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.